MAY 30, 2018 10:30 AM PDT

Inhibitors of NSD2 Discovered by High-Throughput Screening with a Nucleosome Substrate

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Research Scientist, Biology, Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
    Biography
      Dr. Nathan P. Coussens is a Senior Research Scientist in the Division of Pre-Clinical Innovation at the National Center for Advancing Translational Sciences (NCATS). He earned a Ph.D. in biochemistry from the University of Iowa, where he applied structural and biophysical approaches to the study of host-pathogen interactions. As a postdoctoral fellow of the Interdisciplinary Immunology Program at the University of Iowa, he utilized X-ray crystallography and thermodynamic binding studies to inform the development of small molecules that target a host evasion mechanism exploited by families of pathogenic bacteria. Prior to joining NCATS in 2013, Dr. Coussens was a postdoctoral fellow at the National Cancer Institute where he combined biophysical studies, cell biology, and high-resolution imaging to interrogate molecular signaling events initiated by the T cell antigen receptor. At NCATS, Dr. Coussens applies his diverse scientific background to develop and optimize novel biochemical and cell-based assays for high-throughput screening. He works with a highly collaborative and multidisciplinary team to develop small molecule probes relevant to a variety of human diseases. Dr. Coussens also serves as editor-in-chief of the Assay Guidance Manual, a growing online eBook of best practices for preclinical assay development and implementation that has become the go-to resource for scientists in industry and academia.

    Abstract:

    NSD2 catalyzes the mono- and di-methylation of the e-amine of lysine 36 from histone H3, utilizing the methyl donor S-adenosyl-L-methionine. Increased catalytic activity of NSD2, either by overexpression or point mutations, is associated with multiple human cancers. To date, potent, selective and cell-active NSD2 inhibitors have not been described. A platform was established for the discovery of selective NSD2 inhibitors from quantitative high-throughput screening in a 1536-well format using a nucleosome substrate. Active compounds from the primary screen were triaged by a panel of assays and tested against two clinically relevant NSD2 mutants, E1099K and T1150A. Five confirmed inhibitors were further evaluated by a radiolabeled validation assay, surface plasmon resonance studies, methyltransferase profiling, and histone methylation in U-2 OS cells. Several inhibitors bound the NSD2 catalytic SET domain and demonstrated activity in cells, which validates the use of this workflow for the discovery and development of selective NSD2 inhibitors.
     

    Learning Objectives: 

    1. The importance of orthogonal and counter assays for hit selection
    2. The value of assay miniaturization for expensive/limited reagents


    Show Resources
    You May Also Like
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    NOV 18, 2019 07:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUN 26, 2019 09:00 AM PDT
    C.E. CREDITS
    JUN 26, 2019 09:00 AM PDT
    DATE: June 26, 2019TIME: 9:00am PDT, 12:00pm EDT An excessive number of software solutions are available to help manage your clinical, biobank, or biorepository sample inform...
    JUL 30, 2019 10:00 AM PDT
    C.E. CREDITS
    JUL 30, 2019 10:00 AM PDT
    DATE: July 30, 2019TIME: 10:00am PT/ 1:00pm ET The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high...
    Loading Comments...
    Show Resources